206 related articles for article (PubMed ID: 26316711)
21. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
22. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
23. Weight change and risk of cardiovascular disease among adults with type 2 diabetes: more than 14 years of follow-up in the Tehran Lipid and Glucose Study.
Moazzeni SS; Hizomi Arani R; Deravi N; Hasheminia M; Khalili D; Azizi F; Hadaegh F
Cardiovasc Diabetol; 2021 Jul; 20(1):141. PubMed ID: 34253199
[TBL] [Abstract][Full Text] [Related]
24. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
25. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects.
Jin SM; Kim TH; Bae JC; Hur KY; Lee MS; Lee MK; Kim JH
Diabetes Res Clin Pract; 2014 May; 104(2):266-72. PubMed ID: 24630619
[TBL] [Abstract][Full Text] [Related]
26. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
Abbasi F; Chu JW; McLaughlin T; Lamendola C; Leary ET; Reaven GM
Metabolism; 2004 Feb; 53(2):159-64. PubMed ID: 14767866
[TBL] [Abstract][Full Text] [Related]
27. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
[TBL] [Abstract][Full Text] [Related]
28. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of glycemic control in patients with type 2 diabetes mellitus in Chinese communities: a cross-sectional study.
Shan S; Gu L; Lou Q; Ouyang X; Yu Y; Wu H; Bian R
Clin Exp Med; 2017 Feb; 17(1):79-84. PubMed ID: 26695015
[TBL] [Abstract][Full Text] [Related]
30. High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events.
Stoekenbroek RM; Rensing KL; Bernelot Moens SJ; Nieuwdorp M; DeVries JH; Zwinderman AH; Stroes ES; Currie CJ; Hutten BA
Atherosclerosis; 2015 Jun; 240(2):318-23. PubMed ID: 25864162
[TBL] [Abstract][Full Text] [Related]
31. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
32. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Olansky L; Marchetti A; Lau H
Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
[TBL] [Abstract][Full Text] [Related]
33. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
34. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
Yoon NM; Cavaghan MK; Brunelle RL; Roach P
Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
[TBL] [Abstract][Full Text] [Related]
35. The shifting paradigm in the treatment of type 2 diabetes mellitus-A cardiologist's perspective.
Fatima S; Jameel A; Ayesha F; Menzies DJ
Clin Cardiol; 2017 Nov; 40(11):970-973. PubMed ID: 28841228
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
[TBL] [Abstract][Full Text] [Related]
37. Glycemic control and diabetic dyslipidemia in adolescents with type 2 diabetes.
Le PT; Huisingh CE; Ashraf AP
Endocr Pract; 2013; 19(6):972-9. PubMed ID: 23807519
[TBL] [Abstract][Full Text] [Related]
38. Good glycemic control of gestational diabetes mellitus is associated with the attenuation of future maternal cardiovascular risk: a retrospective cohort study.
Yefet E; Schwartz N; Sliman B; Ishay A; Nachum Z
Cardiovasc Diabetol; 2019 Jun; 18(1):75. PubMed ID: 31167664
[TBL] [Abstract][Full Text] [Related]
39. Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia.
Mitrakou A; Katsiki N; Lalic NM
Curr Vasc Pharmacol; 2017; 15(1):19-29. PubMed ID: 27550054
[TBL] [Abstract][Full Text] [Related]
40. Proteomic alterations of HDL in youth with type 1 diabetes and their associations with glycemic control: a case-control study.
Gourgari E; Ma J; Playford MP; Mehta NN; Goldman R; Remaley AT; Gordon SM
Cardiovasc Diabetol; 2019 Mar; 18(1):43. PubMed ID: 30922315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
